MetaVia Inc. — Director's Dealing 2016

Aug 5, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-08-04

Reporting Person: Oniciu Carmen Daniela (VP of PreClinical R&D & Manf.)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	149919	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (2237)		Direct

Footnotes

F1: The Series A Convertible Preferred Stock has no expiration date, and shall convert into shares of common stock, par value $0.001 per share, of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering.